A Study to Evaluate the Effectiveness and Safety of OZURDEX® in Patients With Diabetic Macular Edema But Never Treated (EYEberia)
A 12-month, Prospective, Open-label, Phase 4 Study to Evaluate the Efficacy and Safety of OZURDEX® (Dexamethasone Intravitreal Implant) in Treatment Naïve Patients (According to Standard Clinical Practice) With Diabetic Macular Edema
Sponsor: Allergan
Listed as NCT03953807, this PHASE4 trial focuses on Diabetic Macular Edema and remains completed. Sponsored by Allergan, it has been updated 12 times since 2019, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
12 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE4
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Nov 2022 — Jul 2024 [monthly]
Completed PHASE4
Status: Active Not Recruiting → Completed
-
Sep 2022 — Nov 2022 [monthly]
Active Not Recruiting PHASE4
▶ Show 7 earlier versions
-
Sep 2021 — Sep 2022 [monthly]
Active Not Recruiting PHASE4
Status: Recruiting → Active Not Recruiting
-
May 2021 — Sep 2021 [monthly]
Recruiting PHASE4
-
Apr 2021 — May 2021 [monthly]
Recruiting PHASE4
-
Jan 2021 — Apr 2021 [monthly]
Recruiting PHASE4
-
Mar 2020 — Jan 2021 [monthly]
Recruiting PHASE4
-
Dec 2019 — Mar 2020 [monthly]
Recruiting PHASE4
Status: Not Yet Recruiting → Recruiting
-
Jun 2019 — Dec 2019 [monthly]
Not Yet Recruiting PHASE4
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Allergan
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Barcelona, Spain , Bilbao, Spain , Coimbra, Portugal , Leiria, Portugal , Les Palma, Spain , Lisbon, Portugal , Madrid, Spain , Majadahonda, Spain , Palma de Mallorca, Spain , Pamplona, Spain and 7 more locations